A 27-year-old woman presented with a history of chronic cough and wheezing, recurrent lower respiratory tract infections, and progressive shortness of breath. Asthma had been diagnosed 1 year previously in this patient, and her therapy included an inhaled ␤-adrenergic agonist and glucocorticoid.
What is the diagnosis?
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Diagnosis: Primary tracheobronchial amyloidosis
The differential diagnosis of diffuse narrowing and tracheobronchial wall thickening includes relapsing polychondritis, sarcoidosis, Wegener's granulomatosis, tracheopathia osteoplastica, and tracheobronchitis associated with ulcerative colitis. In tracheopathia osteoplastica, multiple nodules (often calcified) are visualized protruding from the anterior and lateral walls of the central airways. The posterior walls do not contain cartilage; therefore, nodules and calcification are not present. 1 Relapsing polychondritis, a recurrent inflammation of cartilage, involves the laryngeal and tracheal cartilages in Ͼ 50% of patients. 1 A chest CT scan can show marked diffuse tracheobronchial narrowing that is exacerbated by expiration.
The transbronchial biopsy tissue specimens were stained with Congo red dye and exhibited green birefringence under polarized microscopy, a finding characteristic of amyloid. The total protein count was 6.1 g/dL, with a mild hypogammaglobulinemia of 0.4 g/dL. Serum immunoelectrophoresis revealed a small IgM monoclonal spike. Bone marrow aspiration and biopsy specimens demonstrated a normal cellularity (without plasmacytosis) and a normal histology. The liver and myocardial biopsy specimens were normal, consistent with the diagnosis of primary tracheobronchial amyloidosis. 2 Relief of symptoms was achieved with antibiotic, oral glucocorticoid, and nebulized ␤-adrenergic agonist therapies. The proposed treatment includes a trial of interferon therapy and an evaluation for future lung transplantation.
Discussion
Amyloidosis refers to a group of diseases characterized by the extracellular deposition of the complex fibrillar protein amyloid in one or more organs of the body. 2 Amyloidosis is generally classified either according to the anatomic site of involvement (localized or systemic) or to coexisting medical diseases, such as primary or secondary amyloidosis. [2] [3] [4] [5] [6] This latter group includes amyloidosis associated with aging, myeloma, Hodgkin's disease, chronic infections, or inflammatory disorders.
Pulmonary amyloidosis usually occurs in patients with primary systemic amyloidosis. [7] [8] [9] [10] These patients seldom have pulmonary symptoms, although radiographic abnormalities (reticular and reticulonodular opacities) are common. 3, 10, 11 Primary pulmonary amyloidosis is uncommon and manifests as focal or diffuse tracheobronchial or parenchymal amyloidosis. 4, 9, 10, 12 Tracheobronchial disease is usually multifocal and manifests as submucosal plaques. 4, 9 In 14% of patients, the amyloid deposition is solitary and can mimic an endobronchial neoplasm. Patients with tracheobronchial amyloidosis are usually in their fifth or sixth decade of life (range, 27 to 85 years old). 9, 10, 12 Common presenting symptoms include wheeze, chronic cough, hemoptysis, dyspnea, and recurrent pneumonia. 9,10,12 Radiologic manifestations include focal and diffuse thickening and narrowing of the major airways, chronic atelectasis, and bronchiectasis.
Parenchymal amyloidosis manifests either as single or multiple nodules or as diffuse interstitial pulmonary disease. 9, 10, 12 The nodules range in size from 0.3 to 15 cm (mean, 3 cm), and they can calcify. 9, 13 Interstitial pulmonary disease usually manifests as diffuse, small, irregular reticular and reticulonodular parenchymal opacities. 9 Patients are usually Ͼ 50 years of age; patients with parenchymal nodules are typically asymptomatic, and patients with interstitial disease often present with dyspnea. 9, 10, 12, 13 In summary, primary pulmonary amyloidosis is an uncommon disease that can involve the tracheobronchial tree and the pulmonary parenchyma. Patients with tracheobronchial and diffuse interstitial amyloidosis are frequently symptomatic; patients with parenchymal nodules are usually asymptomatic. CT scans typically show parenchymal nodules or diffuse tracheobronchial narrowing and wall thickening. The diagnosis is confirmed by tissue specimens that exhibit green birefringence under polarized microscopy after staining with Congo red dye.
